Michael Kalos

Dr. Michael Kalos is an internationally recognized expert in T cell therapy and immunotherapy and brings over 25 years of experience in the fields of cell therapy, oncology vaccines, and immune-oncology. Previously, Dr. Kalos was Executive Vice President and Head of Research and Development at ArsenalBio. He also served as Vice President, Immuno-oncology and Oncology Cell Therapies, at Janssen, the Pharmaceutical Companies of Johnson and Johnson, and chief scientific officer at Eli Lilly & Company. Dr. Kalos’s academic lab at UPenn played a key role in the early clinical development of Kymriah, including developing the methodologies and strategies to enable a robust pharmacodynamic and mechanistic analysis of CAR T therapies. He obtained his Ph.D. from the University of Minnesota and completed post-doctoral training in the laboratory of Phil Greenberg at the Fred Hutchinson Cancer Research Center.